首页> 外文OA文献 >Neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel dose dense in stage III breast cancer

【2h】

Neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel dose dense in stage III breast cancer

机译：Neoadjuvant Doxorubicin和环磷酰胺，然后是紫杉醇剂量密集在III期乳腺癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Voc Tai Dang; Tu Van Dao; Hieu Van Nguyen; Thuan Van Tran; Thuy Thi Nguyen;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial [J] . Schneeweiss Andreas, Moebus Volker, Tesch Hans, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：激烈剂量 - 致密的Epirubicin，紫杉醇，环磷酰胺与每周紫杉醇，脂质体Doxorubicin（加上三重阴性乳腺癌中的Carboplatin）用于Neoadjuvant治疗高危早期乳腺癌（Geparocto-GBG 84）：随机期III试验
2. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) [J] . Sikov William M., Berry Donald A., Perou Charles M., Journal of Clinical Oncology . 2015,第1期

机译：在每周一次的紫杉醇新辅助治疗中加用卡铂和/或贝伐单抗后加剂量密集的阿霉素和环磷酰胺对II至III期三阴性乳腺癌病理完全缓解率的影响：CALGB 40603（联盟）
3. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) [J] . Sikov William M., Berry Donald A., Perou Charles M., Journal of Clinical Oncology . 2015,第1期

机译：在每周一次的紫杉醇新辅助治疗中加用卡铂和/或贝伐单抗后加剂量密集的阿霉素和环磷酰胺对II至III期三阴性乳腺癌病理完全缓解率的影响：CALGB 40603（联盟）
4. Use of Laser Photomodulation in the Evolution of Oral Mucositis Associated to Cyclophosphamide, Methotrexate, 5-Fluouracil - CMF in 5 Fluouracil + Adriamycin + Cyclophosphamide - FAC Chemotherapy Protocols in Patients with Breast Cancer [C] . Maria de Fatima Lima Ferreira, Fabiola Bastos de Carvalho, Susana C. P. S. de Oliveira, Mechanisms for low-light therapy VIII . 2013

机译：激光光调节在5种氟尿嘧啶+阿霉素+环磷酰胺-FAC化疗方案中与环磷酰胺，甲氨蝶呤，5-氟尿嘧啶-CMF相关的口腔黏膜演变中的应用
5. Coregistration of serial breast MR studies for augmenting neoadjuvant chemotherapy response evaluation in breast cancer patients. [D] . Chittineni, Ruparani. 2008

机译：增强乳腺癌患者新系列辅助化疗反应评估的系列乳房MR研究的核心。
6. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) [O] . William M. Sikov, Donald A. Berry, Charles M. Perou, -1

机译：在每周一次的紫杉醇新辅助治疗中加用卡铂和/或贝伐单抗再加剂量密集的阿霉素和环磷酰胺对II至III期三阴性乳腺癌病理完全缓解率的影响：CALGB 40603（联盟）
7. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer [O] . Julia Foldi, Andrea Silber, Emily Reisenbichler, 2021

机译：Neoadjuvant Durvalumab加上每周Nab-Paclitaxel和剂量 - 致密的多柔比星/三重阴性乳腺癌中的环磷酰胺
8. Enhancement of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine by Immunomodulatory Doses of Cyclophosphamide and Doxorubicin [R] . Emens, L. A. , Jaffee, E. M. 2003

机译：通过环磷酰胺和阿霉素的免疫调节剂量增强同种异体Gm-CsF分泌乳腺癌疫苗

Neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel dose dense in stage III breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅